Результаты поиска

Biomarkers for Early Complications of Endothelial Origin After Allogeneic Hematopoietic Stem Cell Transplantation: Do They Have a Potential Clinical Role?

Endothelial cell (EC) dysfunction causes a number of early and life-threatening post hematopoietic stem cell transplant (HCT) complications that result in a rapid clinical decline. The main early complications are graft-vs.-host disease (GVHD), transplant associated thrombotic microangiopathy (TA-TMA), and sinusoidal obstruction syndrome (SOS). Post-HCT endothelial dysfunction occurs as a result of chemotherapy, infections, and allogeneic reactivity. Despite major advances in transplant immunology and improvements in supportive care medicine, these complications represent a major obstacle for

Рефлексивный ГИЛЬЯЙН-БАРРЕ СИНДРОМ В ХОДЕ С АЗИМПТОМАТИЧЕСКИМ МНОГОЛЕМЕНТОМ МИЛОМЫ, С КОТОРЫМ БУДЕТ ОБРАЩАТЬСЯ С НИЗКИМ РИТЕКСИМАБОМ.

Несмотря на чрезвычайную редкость, синдром Гильен-Барре (ГБС) был признан неврологическим осложнением множественной миэломы с переменной реакцией на плазмеферез (PEX), иммуноглобулины (IVIG) и антимиеломную терапию. В настоящем документе сообщается о случае, когда пациентка с асимптоматической множественной миеломой (АММ), первоначально представлявшая себя как PEX- и IVIG-refractory GBS. После отказа PEX, IVIG и антимиеломатерапии (bortezomib, elphalan и padnison) пациент в конечном итоге успешно лечился ритуксимой с низкой дозой ().100 мг/м2 в неделю four Дозы). Насколько нам известно, это пе

α2-3-sialylated Гликосфинголипиды при нейроинфламмации, иммунитете и запрограммированной смерти клеток: механистические доказательства и регулирование в зависимости от контекста: всеобъемлющий обзор.

α2-3-sialylated glycosphingolids (α2)3-GSLs) являются основными составляющими нейронных мембран и липидных плотов, где они формируют сепарацию рецепторов, комплекс сигналов и связь с клетками. Однако их биологическое воздействие варьируется в зависимости от молекулярного подтипа, типа клеток, стадии заболевания, концентрации и местной микроокружающей среды. В настоящем обзоре обобщены данные о перепончатых изменениях в α2-3-GSL профили и их связи с нейроинфламмацией, иммунной реакцией, протеостазом и запрограммированной клеточной смертностью через болезнь Паркинсона, болезнь Альцгеймера, болез

Полиморфизм меланкортина - генезиалы с воспалением и болезнями.

Рецепторы Меланокортина (МКР) выполняют различные функции: от пигментации кожи, регулирования аппетита, реакции на стресс и когниции, синтеза стероидов и энергетического баланса до регенерации клеток и иммуномодуляции. Генетический полиморфизм с распределением тканей от мозга, лимбической системы и адренальной коры до нейтрофилов, моноцитов и макрофазов проявляется в MCR. Мутации в генах MC1R, MC2R, MC3R и MC4R связаны с риском меланомы, семейной глюкокортикоидной недостаточности, ожирения и типа 2 Диафиозный сахар, соответственно. Тем временем, MC1R, MC2R и MC5R связаны с риском серьезного де

Совпадение в полном тексте источника
… They first induced systemic inflammatory response syndrome (SIRS) using lipopolysaccharide in pigs and recorded hemodynamic responses to delineate the effects of α-MSH analog. … inflammatory response syndrome USFDA U.S. …

Insights Into Late-Onset Rheumatoid Arthritis (LORA): Characteristics (Clinical and Imaging), Comorbidities, and Therapeutic Targets.

Late-onset rheumatoid arthritis (LORA) is defined as rheumatoid arthritis (RA) manifesting after the age of 65 years, although the terminology remains somewhat ambiguous. With the advent of a super-aging society and extended life expectancies, a significant increase in the incidence of LORA is anticipated. In comparison to young-onset RA (YORA), LORA is predominantly characterized by a higher incidence of acute onset, augmented disease activity and constitutional symptoms, a propensity for systemic manifestations, increased erythrocyte sedimentation rate at disease onset, reduced seropositivit

Repurposing Anti-Cancer Drugs for COVID-19 Treatment.

The novel coronavirus disease 2019 (COVID-19) pandemic has caused catastrophic damage to human life across the globe along with social and financial hardships. According to the Johns Hopkins University Coronavirus Resource Center, more than 41.3 million people worldwide have been infected, and more than 1,133,000 people have died as of October 22, 2020. At present, there is no available vaccine and a scarcity of efficacious therapies. However, there is tremendous ongoing effort towards identifying effective drugs and developing novel vaccines. Early data from Adaptive COVID-19 Treatment Trials

Infiltrative and inflammatory systemic disorders involving the pituitary gland.

The hypothalamic-pituitary region can be affected by a wide and heterogeneous group of infiltrative and inflammatory disorders, including granulomatous, histiocytic, storage, infectious, non-pituitary neoplastic, and autoimmune or inflammatory conditions collectively grouped as hypophysitis. Although individually rare, these disorders are increasingly recognized due to growing awareness, wider use of pituitary imaging, and the emergence of immune checkpoint inhibitor-induced hypophysitis. They typically present with hypopituitarism (often including arginine vasopressin deficiency, which, parti

Clonal Hematopoiesis and CAR T Cell Therapy: From Biological Crosstalk to Clinical Implications.

Clonal hematopoiesis (CH) is increasingly recognized as a significant biological phenomenon in aging and cancer, marked by the expansion of hematopoietic stem and progenitor cells harboring somatic mutations in genes associated with myeloid neoplasms. While CH is strongly linked to a spectrum of inflammatory diseases and hematologic malignancies, its role in shaping responses to cancer immunotherapy-especially chimeric antigen receptor (CAR) T cell therapy-has only recently begun to emerge. This review explores the interplay between CH and CAR T cell therapy, highlighting CH prevalence in trea

From the nephrologist's point of view: diversity of causes and clinical features of acute kidney injury.

Acute kidney injury (AKI) is a clinical syndrome with multiple entities. Although AKI implies renal damage, functional impairment or both, diagnosis is solely based on the functional parameters of serum creatinine and urine output. The latest definition was provided by the Kidney Disease Improving Global Outcomes (KDIGO) working group in 2012. Independent of the underlying disease, and even in the case of full recovery, AKI is associated with an increased morbidity and mortality. Awareness of the patient's individual risk profile and the diversity of causes and clinical features of AKI is pivo

Совпадение в полном тексте источника
… inflammatory response syndrome, septic shock, autoimmune diseases, diabetes mellitus A reduced (left ventricular) cardiac pumping function marks the centre of pathogenesis of the cardiorenal syndrome. … Diverse causes and clinical findings of AKI | Clinical findings | Important laboratory values | Urinary findings Acute cardiorenal/renocardial syndrome | Renal and cardiac failure, lung oedema/hypervolemia | ↑BNP | – Sepsis | Systemic inflammatory response syndrome | ↑C-reactive protein, ↑procalcitonin …

Биомаркеры CSF активации B-клеток в множестве склерозов: клиническая перспектива.

Роль клеток B в патофизиологии множественных склерозов (MS) выходит за рамки синтеза антител, включая также модуляцию T лимфоцитов и миелиоидных клеток. Активация B-клеток в рамках центральной нервной системы связана с высвобождением различных антител, цитокинов и химокинов, которые измеряются в биофильтрах, и тем самым служат биомаркерами иммунных процессов, отвечающих за MS. С этой целью биомаркетная характеристика заболевания посредством сочетания хорошо зарекомендовавших себя маркеров, например, иммуноглобулин (Ig) G-индекс (Ig) G, олиголональные полосы Ig, свободные световые цепи Ig с нов

The dual balance of the cytokine network: key messengers of immune activation and triggers of cytokine storm.

The cytokine network is the central regulatory system for intercellular communication within the immune system. Its proper function depends on the dynamic balance between pro-inflammatory and anti-inflammatory cytokines. Through complex positive and negative feedback loops, this balance precisely regulates the intensity and duration of immune responses, thereby playing a critical role in both physiological and pathological states. This review systematically summarizes the compositional features and classification framework of the cytokine network, as well as the mechanisms by which it maintain

Клинические характеристики, диагноз, лечение и прогноз заболевания сывороткой ритуксимаба: ретроспективный анализ 39 Количество зарегистрированных случаев.

Заболевание сывороткой, вызванное ритуксимабом (РИСС), представляет собой необычайно запоздалую гиперчувствительность, характеризующуюся неполной клиническими характеристиками и управлением. Мы намеревались обобщить опубликованные доклады/серии с целью определения клинических моделей, терапевтических стратегий и результатов. МЕТОДЫ: PubMed, EMBASE, Web of Science, WanFang Data и China National Knowledge Infrastructure (CNKI) были найдены отчеты о болезни сыворотки, выпущенные до ноября 31, 2025, используя ключевые слова и свободные текстовые термины (например, "Rituximab", "Serum Bealth", "Ser

Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, and Somatic (VEXAS) Syndrome: A Case Report.

VEXAS is an acronym that stands for the technical terms of key descriptors of the condition: vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic (VEXAS) syndrome, which is a recently identified autoinflammatory disorder primarily affecting men older than 50 years of age. It is commonly associated with a somatic mutation in the X-linked ubiquitin-activating enzyme-encoding UBA1 gene. This condition manifests in a range of hematologic and systemic inflammatory symptoms, such as cytopenias, recurrent fevers, and an elevated risk for hematologic malignancies like myelodysplastic syndrome

Case Report: Endothelial-targeted bridging therapy for a TTP-like phenotype in fulminant iMCD-TAFRO.

BACKGROUND: iMCD-TAFRO (the TAFRO clinical subtype of idiopathic multicentric Castleman disease (iMCD)) is characterized by thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly. Diagnosis is challenging due to its rarity, non-specific early presentation, and overlap with sepsis, lymphoma, and thrombotic microangiopathy (TMA). Endothelial injury is increasingly recognized as a central driver of its severe complications. CASE PRESENTATION: A previously healthy 20-year-old woman presented with rapid progression of fever, anasarca, jaundice, and respiratory failure. Laboratory

Outcomes of Conservative Versus Surgical Treatment of Dropped Head Syndrome in a Single Institution: A Case Series and Review of the Literature.

Dropped head syndrome (DHS), also known as camptocephalia, is characterized by a mobile chin-on-chest deformity from hypotonia of the cervical extensor muscle or hypertonia of the anterior neck muscles. There remains a paucity of quality published literature on this topic, particularly its management. The objective of this study is to identify radiographic and clinical outcomes of surgery as compared to nonsurgical treatment, to summarize the literature, and to create a decision-making paradigm for managing patients with DHS. As such, we report outcomes of our retrospective chart review series

Comprehensive Diagnosis and Management of POEMS Syndrome.

Polyneuropathy Organomegaly, Endocrinopathy, Monoclonal protein and Skin changes syndrome is a rare multisystem condition with a range of manifestations which are often overlooked as trivial comorbidities, until their whole triggers the possibility of the diagnosis. The diagnosis is typically delayed by 12-16 months, by which time patients can be severely disabled. There are no established consensus guidelines. We provide clinicians a comprehensive blueprint for managing POEMS from diagnostic suspicion through the work-up, selection of therapy, follow-up, and treatment of relapse based on publ

Guarding the heart in the era of immunotherapies: insights for cardio-oncology practice.

The advent of cancer immunotherapies, including immune checkpoint inhibitors (ICI), Chimeric antigen receptor (CAR-T) cell therapies, and bispecific antibodies and other immune-activating platforms such as therapeutic vaccines and oncolytic viruses (often used in combination regimens) has revolutionized oncology by improving patient outcomes across diverse malignancies. However, these therapies are increasingly linked to cardiovascular toxicities such as myocarditis, arrhythmias, and heart failure, posing significant clinical challenges. Here we review current evidence on the mechanisms, clini

Novel combinations to improve hematopoiesis in myelodysplastic syndrome.

Myelodysplastic syndrome (MDS) represents a heterogeneous group of clonal hematopoietic disorders, which is characterized by cytopenias in the peripheral blood and bone marrow dysplasia due to ineffective hematopoiesis. Patients with MDS have an increased risk of transformation to acute myeloid leukemia (AML). Although the molecular basis of MDS is heterogeneous, several studies demonstrated the significant contribution of the dysregulated immune system in accelerating MDS progression. The immunosuppressive tumor microenvironment is shown to induce tolerance of MDS blasts, which may result in

Dermatological manifestations of hematologic neoplasms. Part II: nonspecific skin lesions/paraneoplastic diseases.

Cutaneous manifestations occur in the course of hematologic malignancies and precede, accompany or occur late in relation to the diagnosis. They result from paraneoplastic phenomena, tumor infiltrations, immunosuppression resulting from the hematologic disease itself or its treatment. The dermatologist must be aware of these conditions that may be helpful both in the diagnosis of the underlying disease and in reducing patient morbidity. This review (part II) addresses the paraneoplastic dermatological changes associated with systemic hematologic malignancies.

Juvenile-onset Systemic Lupus Erythematosus: Recent Advances in Pathogenesis and Treatment.

PURPOSE OF REVIEW: This review summarizes recent advances in understanding the pathogenesis and therapeutic landscape of juvenile-onset systemic lupus erythematosus (jSLE), with a focus on how emerging genetic and immunologic insights inform patient stratification, targeted treatments, and Treat-to-Target (T2T) approaches in pediatric care. RECENT FINDINGS: Studies of (ultra-)rare gene variants (e.g., affecting TLR7, UNC93B1, PLD4, PTPN2, BACH2) aided in understanding key pathogenic pathways, and allowed linking these to associated clinical phenotypes. Multi-ancestral genomic studies and cumu